Login / Signup

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.

P CacoubM VautierAnne Claire DesboisD SaadounZobair M Younossi
Published in: Alimentary pharmacology & therapeutics (2017)
Extrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti-viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Keyphrases
  • hepatitis c virus
  • hepatitis c virus infection
  • healthcare
  • sars cov
  • human immunodeficiency virus
  • mesenchymal stem cells